ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · IEX Real-Time Price · USD
10.22
+0.26 (2.61%)
At close: Mar 28, 2024, 4:00 PM
10.49
+0.27 (2.64%)
After-hours: Mar 28, 2024, 7:35 PM EDT
Company Description
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.
The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis.
It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals, Inc.
Country | United States |
Founded | 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 24 |
CEO | Richard Lowenthal M.B.A., M.S., MSMSEL |
Contact Details
Address: 11682 El Camino Real, Suite 120 San Diego, California 92130 United States | |
Phone | 858-771-9307 |
Website | ars-pharma.com |
Stock Details
Ticker Symbol | SPRY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001671858 |
ISIN Number | US82835W1080 |
Employer ID | 81-1489190 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Richard Lowenthal M.B.A., M.S., MSMSEL | Founder, President, Chief Executive Officer and Director |
Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder and Chief Medical Officer |
Eric Karas | Chief Commercial Officer |
Dr. Robert Bell Ph.D. | Co-Founder and Chief Science Officer |
Kathleen D. Scott CPA | Chief Financial Officer |
Brian T. Dorsey M.S. | Chief Operations Officer |
Alexander A. Fitzpatrick Esq. | Chief Legal Officer and Secretary |
Daniel Relovsky | Senior Vice President of Marketing |
Harris Kaplan M.B.A. | Executive Vice President of Commercial Strategy |
Justin Chakma | Chief Business Officer and Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 21, 2024 | 10-K | Annual Report |
Mar 21, 2024 | 8-K | Current Report |
Mar 7, 2024 | 8-K | Current Report |
Feb 26, 2024 | 144 | Filing |
Feb 26, 2024 | 144 | Filing |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 9, 2023 | 10-Q | Quarterly Report |
Nov 9, 2023 | 8-K | Current Report |
Sep 25, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |